Table 4 Median Fridericia corrected QT interval (QTcF), and proportion with abnormal ECG findings from baseline to last day of dosing among participants in the efavirenz- (N = 158) and nevirapine- (N = 60) based antiretroviral therapy groups
Time of ECG test | Median (IQR) QTcF in ms | Proportion with QTcF ≥ 450 ms | Proportion with QTcF change > 60 ms from baseline to last day of dosing on day 2 (taken within 2 h of dosing)a | |||
|---|---|---|---|---|---|---|
Efavirenz-based ART group | Nevirapine-based ART group | Efavirenz-based ART group | Nevirapine-based ART group | Efavirenzb-based ART group | Nevirapineb-based ART group | |
NA | NA | n (%) | n (%) | n (%) | n (%) | |
Day 0 | 395 (360–418) | 418 (390–438) | 6 (3.8) | 7 (11.8) | NA | NA |
Day 1 | 403 (383–423) | 418 (388–437) | 10 (6.3) | 6 (10.0) | 19 (12.3) | 1 (1.7) |
Day 2 | 424 (408–442) | 434 (414–459) | 29 (18.4) | 21 (35.0) | 48 (31.2) | 8 (13.3) |
Follow up visit after day 2 (day 7 or 14 of follow up) | 410 (384–436) | 424 (402–437) | 0 | 0 | NA | NA |